Market Research Logo

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

Summary


Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient’s immune system in a general way or aiding the identification of specific antigens associated with the cancer.

The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells. Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.

The report focuses on the key indications of breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer, these indications are the largest in terms of size, with 448, 526, 456, 415 and 374 in active development, respectively. The pipeline is dominated mAbs, cell therapies, small molecules and cancer vaccines.

Scope

  • Global revenue from the cancer immunotherapies market is forecast to increase from $33.7 billion in 2017 to $103.4 billion in 2024, at a compound annual growth rate of 17.4%. What is driving this growth?
  • The leading companies in terms of market share are Celgene, Merck & Co., Bristol-Myers Squibb and Roche. Which of these are forecast to experience the largest growth?
  • There are some key new approvals and late-stage products set to enter the market during the forecast period. Which impact will these drugs have on the market?
  • The market has been dominated by immune checkpoint inhibitors and drugs that target tumor associated antigens. To what extent will these classes of drugs and others dominate the market over the forecast period?
  • There are 3,863 cancer immunotherapy products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Cancer immunotherapy clinical trials have an overall attrition rate of around 96%, what can companies do to maximize their chance of success?
Reasons to buy
  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
  • Analyze the cancer immunotherapy pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at current cancer immunotherapies to provide an insight into the risk associated of attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2017 to 2024. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and certain patent expirations will influence market value.
  • Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Therapy Area Introduction
    • Overview of Key Indications and Symptoms
      • Breast Cancer
        • Table Cancer Immunotherapies Drugs Market, Global, Breast Cancer Histopathological and Molecular Classification, 2018
      • Leukemia
      • Lymphoma
      • Melanoma
      • Non-Small Cell Lung Cancer
    • Diagnosis
      • Breast Cancer
      • Leukemia
      • Lymphoma
      • Melanoma
      • Non-Small Cell Lung Cancer
    • Etiology and Pathophysiology
      • Breast Cancer
      • Leukemia
      • Lymphoma
      • Melanoma
      • Non-Small Cell Lung Cancer
        • Table Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018
    • Epidemiology
      • Table Cancer Immunotherapies Drugs Market, 7MM, Epidemiology of Key Indications, 2016
      • Breast Cancer
        • Table Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016–2023
      • Leukemia
        • Table Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016–2023
      • Lymphoma
        • Table Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016– 2023
      • Melanoma
        • Table Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016–2023
      • Non-Small Cell Lung Cancer
        • Table Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016–2023
    • Prognosis
      • Breast Cancer
        • Table Cancer Immunotherapies Drugs Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival Rate (%), 2016
      • Leukemia
        • Table Cancer Immunotherapies Drugs Market, US, Leukemia Subtype and Five-Year Survival Rates (%), 2016
      • Lymphoma
        • Table Cancer Immunotherapies Drugs Market, US, Lymphoma Subtype and Survival Rates (%), 2016
      • Melanoma
        • Table Cancer Immunotherapies Drugs Market, US, Cutaneous Melanoma Stage and Survival Rates (%), 2016
      • Non-Small Cell Lung Cancer
        • Table Cancer Immunotherapies Drugs Market, US, NSCLC Stage at Diagnosis and Five-Year Relative Survival (%), 2017
    • Treatment
  • Key Marketed Products
    • Overview
      • Table Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
    • Revlimid (lenalidomide) – Celgene
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Revlimid, 2018
      • Table Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006–2024
    • Opdivo (nivolumab) – Ono Pharma/Bristol-Myers Squibb
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Opdivo, 2018
      • Table Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014–2024
    • Keytruda (pembrolizumab) – Merck & Co.
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Keytruda, 2018
      • Table Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014–2024
    • Tecentriq (atezolizumab) – Roche
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Tecentriq, 2018
      • Table Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016–2024
    • Darzalex (daratumumab) – Johnson & Johnson
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Darzalex, 2018
      • Table Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015–2024
    • Imfinzi (durvalumab) – AstraZeneca/Celgene
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications Imfinzi, 2018
      • Table Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017–2024
    • Gardasil/Gardasil 9 (human papillomavirus vaccine) – Merck & Co.
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gardasil, 2018
      • Table Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006–2024
    • Pomalyst/Imnovid (pomalidomide) – Celgene
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Pomalyst, 2018
      • Table Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013–2024
    • Yescarta (axicabtagene ciloleucel) – Gilead Sciences
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yescarta, 2018
      • Table Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018–2024
    • Gazyva (obinutuzumab) – Roche
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gazyva, 2018
      • Table Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013–2024
    • Yervoy (ipilimumab) – Bristol-Myers Squibb
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yervoy, 2018
      • Table Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011–2024
    • Rituxan (rituximab) – Roche/Biogen
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Rituxan, 2018
      • Table Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006–2024
    • Kymriah (tisagenlecleucel) – Novartis
      • Table Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Kymriah, 2018
      • Table Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017–2024
  • Pipeline Landscape Assessment
    • Overview
      • Table Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
    • Pipeline Development Landscape
      • Table Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018
      • Table Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018
      • Table Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018
    • Molecular Targets in the Pipeline
      • Table Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018
      • Table Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018
    • Clinical Trials Landscape
      • Clinical Trial Failure Rates
        • Table Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006–2018
        • Table Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2018
        • Table Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2018
        • Table Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2018
      • Clinical Trial Duration
        • Table Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2018
        • Table Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2018
        • Table Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2018
        • Table Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2018
      • Clinical Trial Size
        • Table Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006–2018
        • Table Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2018
        • Table Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2018
        • Table Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2018
      • Cumulative Clinical Trial Size
        • Table Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006–2018
        • Table Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2018
        • Table Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2018
        • Table Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2018
    • Late-Stage Drugs of the Developmental Pipeline
      • Lisocabtagene maraleucel – Juno Therapeutics/Celgene
        • Table Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018–2024
      • Durvalumab plus Tremelimumab – AstraZeneca
        • Table Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018–2024
      • Tremelimumab – AstraZeneca
        • Table Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018–2024
      • Cemiplimab – Regeneron/Sanofi
        • Table Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019–2024
      • Epacadostat – Incyte Corp
        • Table Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020–2024
      • Axalimogene filolisbac – Advaxis
        • Table Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020–2024
  • Multi-scenario Market Forecast to 2024
    • Overall Market Size
      • Table Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017–2024
      • Table Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Key Products ($bn), 2017–2024
      • Table Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017–2024
    • Generic Penetration
      • Table Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017–2024
    • Revenue Forecast by Molecular Target
      • Immune Checkpoint Proteins
        • Table Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017–2024
      • Tumor Associated Antigens
        • Table Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017–2024
      • Cytokine Signaling
        • Table Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017–2024
      • HPV
        • Table Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017–2024
  • Company Analysis and Positioning
    • Table Figure 56: Cancer Immunotherapies Drugs Market, Global, Company Analysis Matrix, 2017–2024
    • Table Figure 57: Cancer Immunotherapies Drugs Market, Global, Cluster by Growth and Market Share, 2017–2024
    • Revenue and Market Share Analysis by Company
      • Table Cancer Immunotherapies Drugs Market, Global, Forecast Revenue by Company, 2017–2024
      • Table Figure 58: Cancer Immunotherapies Drugs Market, Global, Forecast Market Share by Company (%), 2017–2024
      • Table Figure 59: Cancer Immunotherapies Drugs Market, Global, Companies by Compound Annual Growth Rate (%), 2017–2024
      • Table Figure 60: Cancer Immunotherapies Drugs Market, Global, Revenues by Route of Acquisition, 2017–2024
      • Celgene – Revlimid to Maintain Celgene's Position as Market Leader
        • Table Figure 61: Cancer Immunotherapies Drugs Market, Global, Celgene Annual Revenue Forecast ($bn), 2017–2024
      • Merck & Co. – Keytruda Key to Cancer Immunotherapy Market Growth
        • Table Figure 62: Cancer Immunotherapies Drugs Market, Global, Merck & Co Annual Revenue Forecast ($bn), 2017–2024
      • Bristol-Myers Squibb – Opdivo to Drive Revenue from Cancer Immunotherapies
        • Table Figure 63: Cancer Immunotherapies Drugs Market, Global, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2017–2024
      • Roche – Strong Revenue from Tecentriq and Gazyva Set to Offset Loss from Rituxan
        • Table Figure 64: Cancer Immunotherapies Drugs Market, Global, Roche Annual Revenue Forecast ($bn), 2017–2024
      • AstraZeneca – Revenue from Imfinzi set to Drive Growth amid Growing Immunotherapy Presence
        • Table Figure 65: Cancer Immunotherapies Drugs Market, Global, AstraZeneca Annual Revenue Forecast ($bn), 2017–2024
      • Johnson & Johnson – Darzalex Key to Strong Growth
        • Table Figure 66: Cancer Immunotherapies Drugs Market, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2017–2024
      • Novartis – Diverse Cancer Immunotherapies Portfolio Contributes Small Portion to Overall Revenue
        • Table Figure 67: Cancer Immunotherapies Drugs Market, Global, Novartis Annual Revenue Forecast ($bn), 2017–2024
      • AbbVie – Recent New Approvals to Result in AbbVie Becoming a Leading Player in 2024
        • Table Figure 68: Cancer Immunotherapies Drugs Market, Global, AbbVie Annual Revenue Forecast ($bn), 2018–2024
      • Gilead Sciences – Growth Driven by CAR-T Therapy Yescarta
        • Table Figure 69: Cancer Immunotherapies Drugs Market, Global, Gilead Sciences Annual Revenue Forecast ($bn), 2018–2024
      • Amgen – Rituximab Biosimilar to Drive Growth for Amgen in a Portfolio with No Novel Blockbusters
        • Table Figure 70: Cancer Immunotherapies Drugs Market, Global, Amgen Annual Revenue Forecast ($bn), 2017–2024
    • Market and Pipeline Company Landscape
      • Table Figure 71: Cancer Immunotherapies Drugs Market, Global, High-activity and Late-stage Pipeline Developers by Company Type, 2018
      • Table Figure 72: Cancer Immunotherapies Drugs Market, Global, Overall High-Activity and Late-Stage Pipeline Developers by Level of Cancer Immunotherapies Specialization, 2018
      • Table Figure 73: Cancer Immunotherapies Drugs Market, Global, Proportion of Total Company Revenue Attributed to Cancer Immunotherapies, 2017–2024
  • Strategic Consolidations
    • Licensing Deals
      • Deals by Region, Deal Value and Year
        • Table Figure 74: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Region, Deal Value and Year, 2006–2018
      • Deals by Indication and Deal Value
        • Table Figure 75: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Indication, 2006–2018
      • Deals by Stage of Development and Deal Value
        • Table Figure 76: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Stage of Development and Value, 2006–2018
      • Deals by Molecule Type, Molecular Target and Deal Value
        • Table Figure 77: Cancer Immunotherapies Drugs Market, Global, Licensing Deals by Molecule Type and Molecular Target, 2006–2018
      • Table for Licensing Deals with Disclosed Deal Value
        • Table Cancer Immunotherapies Drugs Market, Global, Licensing Deals, 2006–2018
    • Co-development Deals
      • Deals by Region, Deal Value and Year
        • Table Figure 78: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Region, Year and Value, 2006–2018
      • Deals by Indication and Deal Value
        • Table Figure 79: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Indication, 2006–2018
      • Deals by Stage of Development and Deal Value
        • Table Figure 80: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Stage of Development and Value, 2006–2018
      • Deals by Molecule Type, Molecular Target and Deal Value
        • Table Figure 81: Cancer Immunotherapies Drugs Market, Global, Co-development Deals by Molecule Type and Molecular Target, 2006–2018
      • Table for Co-development Deals with Disclosed Deal Value
        • Table Cancer Immunotherapies Drugs Market, Global, Co-development Deals, 2006–2018
  • Appendix
    • References
    • Figures of All Clinical Stage Pipeline Products
      • Table Figure 82: Cancer Immunotherapies Drugs Market, Global, Table of all Clinical Stage Pipeline Products, 2018
    • Abbreviations
    • Disease List
    • Methodology
      • Coverage
      • Secondary Research
      • Market Size and Revenue Forecasts
      • Pipeline Analysis
      • Competitive Landscape
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report